BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fianlimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Fianlimab\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04989946-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fianlimab: Phase 1/2 readout est. (NCT04989946)
DESCRIPTION:Fianlimab\, phase 1/2.\nStudy: Androgen Deprivation\, With or W
 ithout pTVG-AR\, and With or Without T-Cell Checkpoint Blockade\, in Patie
 nts With Newly Diagnosed\, High-Risk Prostate Cancer\nEstimated primary co
 mpletion: December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/fianlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04989946
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608291-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Fianlimab: Phase 3 readout est. (NCT05608291)
DESCRIPTION:Fianlimab\, phase 3\, Melanoma.\nStudy: A Trial to See if the C
 ombination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab fo
 r Preventing or Delaying Melanoma From Coming Back After it Has Been Remov
 ed With Surgery\nEstimated primary completion: 15 January 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/fianlimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05608291
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246916-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Fianlimab: Phase 3 readout est. (NCT06246916)
DESCRIPTION:Fianlimab\, phase 3\, Melanoma.\nStudy: A Study With Combinatio
 ns of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advan
 ced or Metastatic Melanoma (Harmony Head-to-Head)\nEstimated primary compl
 etion: 22 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /fianlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06246916
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865339-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Fianlimab: Phase 2 readout est. (NCT06865339)
DESCRIPTION:Fianlimab\, phase 2.\nStudy: Thoracic Radiotherapy and Inhibiti
 on of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer\nEsti
 mated primary completion: August 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/fianlimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06865339
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06594991-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Fianlimab: Phase 2 readout est. (NCT06594991)
DESCRIPTION:Fianlimab\, phase 2\, Melanoma.\nStudy: A Study of Fianlimab\, 
 Cemiplimab\, and Ipilimumab in People With Melanoma\nEstimated primary com
 pletion: September 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/fianlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06594991
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05785767-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Fianlimab: Phase 2/3 readout est. (NCT05785767)
DESCRIPTION:Fianlimab\, phase 2/3.\nStudy: A Study to Learn if a Combinatio
 n of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective fo
 r Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)\nEst
 imated primary completion: 28 September 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/fianlimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05785767
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03233139-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Fianlimab: Phase 1 readout est. (NCT03233139)
DESCRIPTION:Fianlimab\, phase 1.\nStudy: Safety and Pharmacokinetics of Cem
 iplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Jap
 anese Adult Patients With Advanced Malignancies\nEstimated primary complet
 ion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/fianlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03233139
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06887088-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Fianlimab: Phase 2 readout est. (NCT06887088)
DESCRIPTION:Fianlimab\, phase 2\, Melanoma.\nStudy: Encorafenib and biNimet
 inib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant mel
 anOma and Symptomatic Brain Metastases\nEstimated primary completion: Janu
 ary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fianlimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06887
 088
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06699602-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Fianlimab: Phase 2 readout est. (NCT06699602)
DESCRIPTION:Fianlimab\, phase 2.\nStudy: A Study of Cemiplimab and Fianlima
 b in People With Clear Cell Renal Cell Carcinoma\nEstimated primary comple
 tion: February 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 fianlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06699602
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05137054-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20280325
DTEND;VALUE=DATE:20280326
SUMMARY:Fianlimab: Phase 1 readout est. (NCT05137054)
DESCRIPTION:Fianlimab\, phase 1.\nStudy: A Study to Examine the Effects of 
 Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments fo
 r Adult Participants With Multiple Myeloma That is Resistant to Current St
 andard of Care Treatments\nEstimated primary completion: 25 March 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/fianlimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05137054
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07234058-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Fianlimab: Phase 2 readout est. (NCT07234058)
DESCRIPTION:Fianlimab\, phase 2.\nStudy: Trial Assessing Fianlimab Plus Cem
 iplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With
  Pleural Mesothelioma\nEstimated primary completion: May 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/fianlimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07234058
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511036-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20280524
DTEND;VALUE=DATE:20280525
SUMMARY:Fianlimab: Phase 2 readout est. (NCT07511036)
DESCRIPTION:Fianlimab\, phase 2\, Melanoma.\nStudy: PROSECCO: A Phase 2\, S
 ingle Arm\, Neoadjuvant Study Evaluating Combination Cemiplimab\, Fianlima
 b\, And Ipilimumab In Patients With Surgically Resectable Melanoma\nEstima
 ted primary completion: 24 May 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/fianlimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07511036
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769698-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20280604
DTEND;VALUE=DATE:20280605
SUMMARY:Fianlimab: Phase 2 readout est. (NCT06769698)
DESCRIPTION:Fianlimab\, phase 2.\nStudy: A Study to See if Giving Fianlimab
  and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recur
 rent or Metastatic Head and Neck Squamous Cell Carcinoma\nEstimated primar
 y completion: 4 June 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/fianlimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06769698
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06787612-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Fianlimab: Phase 2 readout est. (NCT06787612)
DESCRIPTION:Fianlimab\, phase 2.\nStudy: Investigation of Ubamatamab Combin
 ation Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
 \nEstimated primary completion: 30 June 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/fianlimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06787612
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04590326-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20281108
DTEND;VALUE=DATE:20281109
SUMMARY:Fianlimab: Phase 1/2 readout est. (NCT04590326)
DESCRIPTION:Fianlimab\, phase 1/2.\nStudy: A Study to Find Out How Safe REG
 N5668 is and How Well it Works In Adult Women When Given With Either Cemip
 limab\, or Cemiplimab + Fianlimab\, or Ubamatamab\nEstimated primary compl
 etion: 8 November 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/fianlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04590326
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527325-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Fianlimab: Phase 2 readout est. (NCT07527325)
DESCRIPTION:Fianlimab\, phase 2\, Melanoma.\nStudy: Fianlimab&Cemiplimab as
  TotalNeoadj The (TNT) ForMelanoma\nEstimated primary completion: 1 Februa
 ry 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/fianlimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075273
 25
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223541-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Fianlimab: Phase 2 readout est. (NCT07223541)
DESCRIPTION:Fianlimab\, phase 2.\nStudy: Cemiplimab or Cemiplimab and Fianl
 imab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcino
 ma\nEstimated primary completion: August 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/fianlimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07223541
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07179315-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Fianlimab: Phase 2 readout est. (NCT07179315)
DESCRIPTION:Fianlimab\, phase 2.\nStudy: A Study Comparing Two Immunotherap
 y Options for Human Papillomavirus Positive HPV-Positive Head and Neck Can
 cer After Treatment\nEstimated primary completion: 30 November 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/fianlimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07179315
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07188896-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Fianlimab: Phase 2 readout est. (NCT07188896)
DESCRIPTION:Fianlimab\, phase 2.\nStudy: A Randomized Trial of Fianlimab an
 d Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Adv
 anced Renal Cell Carcinoma (RCC)\nEstimated primary completion: 30 Novembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/fianlimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0718889
 6
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224022-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Fianlimab: Phase 2 readout est. (NCT07224022)
DESCRIPTION:Fianlimab\, phase 2.\nStudy: Cemiplimab With Fianlimab for Rese
 ctable Non-Metastatic Colon Cancer\nEstimated primary completion: 31 Decem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fianlimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07224
 022
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800015-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20300116
DTEND;VALUE=DATE:20300117
SUMMARY:Fianlimab: Phase 2/3 readout est. (NCT05800015)
DESCRIPTION:Fianlimab\, phase 2/3.\nStudy: A Trial to Learn How the Combina
 tion of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cem
 iplimab and Chemotherapy for Treating Adult Patients With Advanced Non-sma
 ll Cell Lung Cancer\nEstimated primary completion: 16 January 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/fianlimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05800015
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06205836-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Fianlimab: Phase 2 readout est. (NCT06205836)
DESCRIPTION:Fianlimab\, phase 2.\nStudy: Cemiplimab With or Without Fianlim
 ab to Treat Older Patients With Localized or Locally Advanced MSI-H Colore
 ctal Cancer\nEstimated primary completion: May 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/fianlimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06205836
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281768-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Fianlimab: Phase 2 readout est. (NCT07281768)
DESCRIPTION:Fianlimab\, phase 2.\nStudy: Capecitabine/Oxaliplatin Chemother
 apy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanc
 ed Rectal Cancer\nEstimated primary completion: July 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/fianlimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07281768
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06848088-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20301009
DTEND;VALUE=DATE:20301010
SUMMARY:Fianlimab: Phase 2 readout est. (NCT06848088)
DESCRIPTION:Fianlimab\, phase 2\, Melanoma.\nStudy: A Study to Learn About 
 the Long-Term Health of Adult Participants From a Previous Study of a New 
 Melanoma Treatment\nEstimated primary completion: 9 October 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/fianlimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06848088
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07808515-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20301113
DTEND;VALUE=DATE:20301114
SUMMARY:Fianlimab: Phase 2 readout est. (NCT07808515)
DESCRIPTION:Fianlimab\, phase 2.\nStudy: A Study Comparing Cemiplimab-based
  Treatments for Adult Participants With Locally Advanced Basal Cell Skin C
 ancer (laBCC)\nEstimated primary completion: 13 November 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/fianlimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07808515
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Fianlimab: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Fianlimab\, phase 2.\nStudy: I-SPY TRIAL: Neoadjuvant and Perso
 nalized Adaptive Novel Agents to Treat Breast Cancer\nEstimated primary co
 mpletion: December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/fianlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT01042379
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918132-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20301202
DTEND;VALUE=DATE:20301203
SUMMARY:Fianlimab: Phase 2 readout est. (NCT06918132)
DESCRIPTION:Fianlimab\, phase 2.\nStudy: Cemiplimab and Fianlimab Before Su
 rgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer\nEstim
 ated primary completion: 2 December 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/fianlimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06918132
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07346196-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20310822
DTEND;VALUE=DATE:20310823
SUMMARY:Fianlimab: Phase 2 readout est. (NCT07346196)
DESCRIPTION:Fianlimab\, phase 2.\nStudy: A Trial of Locoregionally Advanced
  Squamous Cell Carcinoma of The Head and Neck\nEstimated primary completio
 n: 22 August 2031. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fi
 anlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07346196
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07567469-2221@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20320827
DTEND;VALUE=DATE:20320828
SUMMARY:Fianlimab: Phase 1/2 readout est. (NCT07567469)
DESCRIPTION:Fianlimab\, phase 1/2.\nStudy: A Safety and Efficacy Study of C
 ombined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent
  or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma\nEstimat
 ed primary completion: 27 August 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/fianlimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07567469
URL:https://assetmemo.bio/drug/fianlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
